Biopsy (NCT05775471)

Name: Biopsy trial for Renal Pelvis and Ureter Urothelial Carcinoma (NCT05775471)
Uploaded: 2026-10-31T21:51:01.555Z
Duration: 1 min 26 s
Description: Biopsy trial for Renal Pelvis and Ureter Urothelial Carcinoma (NCT05775471). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05775471.

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer: a one-minute explainerNCT057754711 min

Biopsy trial for Renal Pelvis and Ureter Urothelial Carcinoma (NCT05775471). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with high-risk urothelial cancer in the kidney's collecting system or ureter. Patients must qualify for surgery. Previous checkpoint immunotherapy or enfortumab vedotin is excluded.

The idea: enfortumab vedotin carries a cell-division-blocking payload to Nectin4-bearing cells; pembrolizumab releases the PD1 immune brake. Both are infused before removal of the kidney and ureter. Pembrolizumab alone follows surgery. Researchers measure tumor response and recurrence; imaging and blood, urine, tissue samples support assessments.

This phase 2 study plans 21 patients. Karim Chamie leads at UCLA, Los Angeles, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.